SCHEMBL25758835

SCHEMBL25758835

CC(C)NC(=O)c1nc2c(Cl)ccc(Cl)c2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.42
POLB P06746 1/20 0.41
ALPL P05186 2/20 0.39
BRAF P15056 1/20 0.38
EIF2AK3 Q9NZJ5 1/20 0.38
TSHR P16473 2/20 0.36
LMNA P02545 1/20 0.36
EGLN1 Q9GZT9 2/20 0.35
CASP1 P29466 1/20 0.35
RECQL P46063 1/20 0.35
RIPK1 Q13546 1/20 0.34
PRKCZ Q05513 1/20 0.34
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25758898 0.88 PDE4A (0.43) ALOX15POLBPDE4APDE4BPDE4C
SCHEMBL25812244 0.86 LMNA (0.49) POLBLMNASMN1; SMN2
SCHEMBL24190232 0.80 F2 (0.40) ALPLTSHRLMNACYP1A2SMN1; SMN2
SCHEMBL24028569 0.80 POLB (0.42) ALOX15POLBALPLTSHRLMNA
SCHEMBL24019965 0.79 ALPL (0.39) POLBALPLTSHRLMNARIPK1
SCHEMBL25758900 0.77 ALOX15 (0.40) ALOX15POLBALPLEGLN1SMN1; SMN2
SCHEMBL23824446 0.76 KDM4E (0.41) TSHRLMNAEGLN1ADORA2AADORA2B
SCHEMBL24019958 0.74 HRH4 (0.53) ALOX15POLBALPLEGLN1RECQL
SCHEMBL24740638 0.73 ALOX15 (0.42) ALOX15POLBALPLEGLN1RIPK1
SCHEMBL24019690 0.71 ALOX15 (0.40) ALOX15POLBTSHRLMNAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF Pardes Biosciences, Inc. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212152-A1 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF CTRL, CTSL, CTSV ALOX15 1455/4885POLB 2188/4885ALPL 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.